New hope for pancreatic cancer: experimental drug combo aims to shrink tumors
NCT ID NCT07131514
Summary
This study is testing a new combination of drugs (HRS-4642, gemcitabine, albumin-bound paclitaxel, and adebrelimab) for people with pancreatic cancer that doctors believe can be removed with surgery. The goal is to see if giving these drugs both before surgery (to shrink the tumor) and after surgery (to prevent return) is safe and effective. The trial will enroll about 30 adults with certain types of operable pancreatic cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.